A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

NCT02937675 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped patient recruitment

Conditions

Lymphoma

Interventions

DRUG: Tomivosertib (eFT-508)

Sponsor

Effector Therapeutics